Samples (n = 163) were evaluated from the tumors of patients with oral squamous carcinoma; 31.0% (9/29) of stage T1 tumor samples, 22.4% (17/76) of stage T2 tumor samples, 22.9% (8/35) of stage T3 tumor samples, and 17.4% (4/23) of stage T4 tumor samples were positive for FOXC2 expression. Here, FOXC2 is linked to neoplasm.